Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Ifetroban Sodium

Once daily oral ifetroban

DRUG

Placebo

Matching oral placebo

Trial Locations (17)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

14642

RECRUITING

University of Rochester, Rochester

19140

RECRUITING

Temple University Hospital, Philadelphia

27514

RECRUITING

UNC Chapel Hill, Chapel Hill

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

33125

RECRUITING

Miami VA Health System, Miami

37055

RECRUITING

Pulmonary & Sleep Specialists, Dickson

40202

RECRUITING

University of Louisville, Louisville

46202

RECRUITING

Indiana University Health, Indianapolis

48073

RECRUITING

Beaumont Hospital, Royal Oak, Royal Oak

57108

RECRUITING

Avera Research Institute, Sioux Falls

60611

RECRUITING

Northwestern Medicine, Chicago

66160

RECRUITING

University of Kansas, Kansas City

75020

RECRUITING

Premier Pulmonary Critical Care and Sleep Medicine, Denison

75246

RECRUITING

Baylor University Medical Center, Dallas

94143

RECRUITING

University of California San Francisco, San Francisco

97701

RECRUITING

Bend Memorial Hospital, Bend

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY

NCT05571059 - Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter